Cost-effectiveness of herpes zoster vaccination in patients with rheumatoid arthritis
Authors' conclusion
Vaccinating patients with RA using RZV results in better health at higher cost compared with no vaccination. Under the assumptions made, vaccination is likely to be considered cost-effective for patients with RA.
Study context
- Population
- Hypothetical cohort of patients with rheumatoid arthritis (RA)hypothetical cohort
- Participants
- 10,000 participants
- Exposure
- Adjuvanted recombinant zoster vaccine vs no vaccination
- Outcome
- ICER (EUR per QALY) vs cost-effectiveness threshold of EUR 23 650 per QALY
- Follow-up
- Lifetime
Methodological detailsdecision-analytic Markov model, five health states, hypothetical cohort, lifetime perspective, healthcare perspective, 4% annual discounting, one-way and probabilistic sensitivity analyses
- Decision-analytic Markov model
- Five health states
- Hypothetical cohort
- Lifetime perspective
- Healthcare perspective
- 4% annual discounting
- One-way and probabilistic sensitivity analyses
Main finding
As reported in the abstract
Incremental cost-effectiveness ratio (ICER), vaccination vs no vaccination
EUR 11 205/QALY
Herpes zoster (HZ) cases averted by vaccination per 10 000 patients with RA vaccinated
2550
Postherpetic neuralgia (PHN) cases averted by vaccination per 10 000 patients with RA vaccinated
1303
Probability recombinant zoster vaccine (RZV) cost-effective at threshold EUR 23 650 per QALY (probabilistic analysis)
98%
Observational data: associations, not effects.
Further findings
HZ and PHN cases averted per 10 000 patients with RA vaccinated
- Reduction in HZ cases
- 2550
- Reduction in PHN cases
- 1303
One-way sensitivity analyses
- Results particularly sensitive to probability of developing PHN as a sequela of HZ
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →